Close Menu

NEW YORK – Japan's Ministry of Health, Labor and Welfare has approved Myriad Genetics' BRACAnalysis Diagnostic System for identifying breast cancer patients with germline BRCA1 and BRCA2 mutations. 

The approval allows physicians in Japan to order BRACAnalysis for women with breast cancer who meet certain criteria established by the Japanese Organization of Hereditary Breast and Ovarian Cancer (JBHBOC). Patients who test positive for a deleterious BRCA1/2 mutation may then be recommended for prophylactic surgeries or targeted treatments. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.